Cypress Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Cypress Capital Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$930K	Buy	15,326 +8,446	+123%	+$492K	0.5%	38
2025 Q4	$371K	Sell	6,880 -10,116	-60%	-$487K	0.2%	57
2025 Q3	$767K	Sell	16,996 -886	-5%	-$41.4K	0.44%	44
2025 Q2	$828K	Buy	17,882 +37	+0.2%	+$1.82K	0.52%	40
2025 Q1	$1.09M	Sell	17,845 -22	-0.1%	-$1.28K	0.76%	25
2024 Q4	$1.01M	Buy	+17,867	New	+$998K	0.79%	26

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cypress Capital Advisors's BMY Position: Q1 2026 in Review

Cypress Capital Advisors increased its Bristol-Myers Squibb (BMY) stake by 123% in Q1 2026, buying an estimated $492K and bringing the position to 15,326 shares worth $930K. The position accounts for 0.5% of the portfolio, ranked #38.

Cypress Capital Advisors first reported a position in BMY in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.09M in Q1 2025. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Cypress Capital Advisors held 15,326 shares of Bristol-Myers Squibb worth $930K as of Q1 2026.
Cypress Capital Advisors bought 8,446 Bristol-Myers Squibb shares in Q1 2026, an estimated $492K.
Bristol-Myers Squibb made up 0.5% of Cypress Capital Advisors's portfolio in Q1 2026, its #38 holding.
Cypress Capital Advisors first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 6 quarters since.
Cypress Capital Advisors's Bristol-Myers Squibb position peaked at $1.09M in Q1 2025.
2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Cypress Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.